News

News

Announcements and coverage from Colt Ventures and our portfolio companies.

2026

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

Read

Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

Read
2024

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

Read

This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

Read

BlossomHill Therapeutics Closes $100 Million Series B Financing

Read
2023

Odyssey Therapeutics Announces $101 Million Series C Financing

Read

Colt Ventures Continues Energy Acquisition Strategy Through Purchase Of Western Haynesville and Permian Oil & Gas Mineral Interests Covering Approximately 8,000 Gross Acres

Read

ReCode Therapeutics Announces Closing of Extension to Series B Financing

Read

Colt Ventures Acquires Core Haynesville Shale Mineral and Royalty Interests Covering up to 40,000 Gross Acres

Read
2022

Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies

Read

Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing

Read

Rumble Completes Business Combination with CF Acquisition Corp. VI

Read

ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M

Read
2021

Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines

Read

Rumble Inc., The Neutral Video Platform, to go Public Through Combination With Cantor Fitzgerald's CF Acquisition Corp. VI (Nasdaq: CFVI)

Read

ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

Read

EBY - The Authority in Seamless Underwear - Announces $6 Million in Series A Funding and the Launch of their Limited Edition Seamless Luxe Collection

Read

ERASCA announces pricing of upsized initial public offering

Read
2020

Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease

Read

Silverback Therapeutics Announces Pricing of Initial Public Offering

Read

Erasca Raises $200 Million Series B Financing

Read

ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

Read

Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing

Read

The Five Revolutions in Cancer Treatment

Read